T1D Fund

T1D Fund company information, Employees & Contact Information

Explore related pages

Related company profiles:

Launched in 2016, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through equity investments. The Fund co-invests with venture capital and biopharma in support of early-stage companies pursuing disease-modifying therapies and potential cures for T1D. A core element of our mission is to rapidly advance promising therapies through development and ultimately regulatory approval. The Fund works in close partnership with Breakthrough T1D (formerly JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust—two of the leading global organizations committed to supporting the T1D community and to advancing T1D research and innovation. Led by a deeply experienced team of healthcare and investing professionals, the Fund leverages its vast research, clinical, regulatory, and medical affairs network on behalf of its portfolio companies. Capitalized through philanthropic dollars, the Fund makes investments in biotech companies and recycles returns into new investments, thereby extending the impact of its donors’ contributions.

Company Details

Employees
17
Address
50 Milk St, Boston,massachusetts 02109,united States
Industry
Venture Capital And Private Equity Principals
NAICS
Miscellaneous Intermediation
Keywords
Manager jobs.
HQ
Boston, Massachusetts
Looking for a particular T1D Fund employee's phone or email?

T1d Fund Questions

News

The T1D Fund Appoints Lucio Iannone, Ph.D., as Managing Director - citybiz

The T1D Fund Appoints Lucio Iannone, Ph.D., as Managing Director citybiz

Discover the T1D Fund: A Breakthrough T1D Venture - Breakthrough T1D

Discover the T1D Fund: A Breakthrough T1D Venture Breakthrough T1D

The T1D Fund Announces Daniel McNamara as Head of Strategy & Industry Engagement to Grow the T1D Fund Brand and Drive Greater Interest in T1D Investments - PR Newswire

The T1D Fund Announces Daniel McNamara as Head of Strategy & Industry Engagement to Grow the T1D Fund Brand and Drive Greater Interest in T1D Investments PR Newswire

Joseph M. Reh - Wilkes-Barre Citizens' Voice

Joseph M. Reh Wilkes-Barre Citizens' Voice

vTv Therapeutics Announces $80 Million Private Placement - GlobeNewswire

vTv Therapeutics Announces $80 Million Private Placement GlobeNewswire

The T1D Fund Appoints Elizabeth Mily as CEO - citybiz

The T1D Fund Appoints Elizabeth Mily as CEO citybiz

JDRF T1D Fund, a Leading Disease-Focused Venture Philanthropy Fund, Appoints Sylvia Tobé as Managing Director - Business Wire

JDRF T1D Fund, a Leading Disease-Focused Venture Philanthropy Fund, Appoints Sylvia Tobé as Managing Director Business Wire

Immunocore Secures $130 Million Series B Financing - General Atlantic

Immunocore Secures $130 Million Series B Financing General Atlantic

The JDRF T1D Fund is Using a Combination of Venture Capital and Philanthropy to Drive Cures for Type 1 Diabetes - Causeartist

The JDRF T1D Fund is Using a Combination of Venture Capital and Philanthropy to Drive Cures for Type 1 Diabetes Causeartist

San Jose Sharks, Forward Luke Kunin Collaborate on the Luke Kunin T1D Fund Merchandise Collection - NHL.com

San Jose Sharks, Forward Luke Kunin Collaborate on the Luke Kunin T1D Fund Merchandise Collection NHL.com

Disease-Modifying Therapies May Offset Type 1 Diabetes Costs - Breakthrough T1D

Disease-Modifying Therapies May Offset Type 1 Diabetes Costs Breakthrough T1D

Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing - PR Newswire

Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing PR Newswire

Breakthrough T1D T1D Fund Invests in vTv Therapeutics - Breakthrough T1D

Breakthrough T1D T1D Fund Invests in vTv Therapeutics Breakthrough T1D

Lilly Acquires Protomer Technologies - citybiz

Lilly Acquires Protomer Technologies citybiz

Eli Lilly Acquires Breakthrough T1D T1D Fund Portfolio Company Protomer Technologies - Breakthrough T1D

Eli Lilly Acquires Breakthrough T1D T1D Fund Portfolio Company Protomer Technologies Breakthrough T1D

Semma Therapeutics Acquired by Major Biopharma Company - Breakthrough T1D

Semma Therapeutics Acquired by Major Biopharma Company Breakthrough T1D

Top T1D Fund Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant